NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
vTv Therapeutics Inc. VTVT
13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-27.0M
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 0.00
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -27.0
5M10M-20M-40M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
Operating margin
Net margin
FY2024 · Operating -2377.6% · Net ·
-5000%-10000%-15000%
201320192025
ROE
Not applicable: equity was zero or negative in this period, so return on equity has no meaning.
Three returns, three denominators.
Each USD of equity lost 70 cents this year.
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | ◌ | −3.20 | −9.71 | −9.98 | −8.29 | −0.18 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −70.4 | — | — | — | — | — | — | — | — | — | — | — | — |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 37 reconciliationsAUDITED
Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. 13 checks were skipped: EPS is not tagged before 2020.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013